Literature DB >> 18322982

Rapid response of nail psoriasis to etanercept.

Efstathios Rallis, Evgenia Stavropoulou, Dimitris Rigopoulos, Constantinos Verros.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322982

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  7 in total

1.  Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study.

Authors:  María Denise Takahashi; Edgardo Néstor Chouela; Gladys Leon Dorantes; Ana Maria Roselino; Jesùs Santamaria; Miguel Angel Allevato; Tania Cestari; Maria Eugenia Manzanera de Aillaud; Fernando Miguel Stengel; Daiana Licu
Journal:  Arch Drug Inf       Date:  2010-03

2.  Nail Lichen Planus: Successful Treatment with Etanercept.

Authors:  N Irla; T Schneiter; E Haneke; N Yawalkar
Journal:  Case Rep Dermatol       Date:  2010-10-21

Review 3.  New insight into the pathogenesis of nail psoriasis and overview of treatment strategies.

Authors:  Alessandra Ventura; Mauro Mazzeo; Roberta Gaziano; Marco Galluzzo; Luca Bianchi; Elena Campione
Journal:  Drug Des Devel Ther       Date:  2017-08-30       Impact factor: 4.162

Review 4.  Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis.

Authors:  Nilendu Sarma
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

5.  Treatment of nail psoriasis: common concepts and new trends.

Authors:  Yasemin Oram; A Deniz Akkaya
Journal:  Dermatol Res Pract       Date:  2013-05-13

Review 6.  Nail Psoriasis: A Review of Treatment Options.

Authors:  Marcel C Pasch
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 7.  Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.

Authors:  Eckart Haneke
Journal:  Psoriasis (Auckl)       Date:  2017-10-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.